MX362517B - Forma cristalina de un inhibidor de transcriptasa inversa. - Google Patents
Forma cristalina de un inhibidor de transcriptasa inversa.Info
- Publication number
- MX362517B MX362517B MX2015003767A MX2015003767A MX362517B MX 362517 B MX362517 B MX 362517B MX 2015003767 A MX2015003767 A MX 2015003767A MX 2015003767 A MX2015003767 A MX 2015003767A MX 362517 B MX362517 B MX 362517B
- Authority
- MX
- Mexico
- Prior art keywords
- hiv
- aids
- crystalline form
- oxo
- methyl
- Prior art date
Links
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 6
- 208000030507 AIDS Diseases 0.000 abstract 4
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 abstract 3
- 206010001513 AIDS related complex Diseases 0.000 abstract 2
- 230000001506 immunosuppresive effect Effects 0.000 abstract 2
- -1 4-methyl-5 -oxo-4,5 -dihydro-1H -1,2, 4-triazol-3 -yl Chemical group 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 208000001388 Opportunistic Infections Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705780P | 2012-09-26 | 2012-09-26 | |
| PCT/US2013/060787 WO2014052171A1 (en) | 2012-09-26 | 2013-09-20 | Crystalline form of a reverse transcriptase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003767A MX2015003767A (es) | 2015-07-14 |
| MX362517B true MX362517B (es) | 2019-01-21 |
Family
ID=50388877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003767A MX362517B (es) | 2012-09-26 | 2013-09-20 | Forma cristalina de un inhibidor de transcriptasa inversa. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9150539B2 (OSRAM) |
| EP (1) | EP2900240B1 (OSRAM) |
| JP (2) | JP6387349B2 (OSRAM) |
| CN (2) | CN109384765A (OSRAM) |
| BR (1) | BR112015005997A8 (OSRAM) |
| CA (1) | CA2882947A1 (OSRAM) |
| ES (1) | ES2773105T3 (OSRAM) |
| MX (1) | MX362517B (OSRAM) |
| WO (1) | WO2014052171A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9598397B2 (en) | 2013-12-04 | 2017-03-21 | Merck Sharp & Dohme Corp. | Process for making reverse transcriptase inhibitors |
| WO2018175271A1 (en) * | 2017-03-24 | 2018-09-27 | Merck Sharp & Dohme Corp. | Formulation for parenteral administration |
| KR20220130698A (ko) * | 2019-12-20 | 2022-09-27 | 에피자임, 인코포레이티드 | Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7309700B2 (en) * | 2004-04-02 | 2007-12-18 | Boehringer Ingelheim International Gmbh | Crystalline forms of 5,11-dihydro-11-ethyl-5-methyl-8-{2-{(1-oxido-4-quinolinyl)oxy}ethyl}-6H-dipyrido[3,2-b:2′,3′-e] [1,4]diazepin-6-one |
| CN1993332B (zh) * | 2004-07-27 | 2011-04-06 | 弗·哈夫曼-拉罗切有限公司 | 作为非核苷逆转录酶抑制剂的苄基三唑酮化合物 |
| JP5341881B2 (ja) * | 2007-05-30 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | トリアゾロン類の製造方法 |
| MX2010005483A (es) * | 2007-11-20 | 2010-06-11 | Merck Sharp & Dohme | Inhibidores de transcriptasa inversa no nucleosidos. |
| HUE031785T2 (en) * | 2010-03-30 | 2017-08-28 | Merck Canada Inc | Pharmaceutical composition comprising a non-nucleoside reverse transcriptase inhibitor |
| EP2558093A4 (en) * | 2010-04-08 | 2013-10-02 | Merck Sharp & Dohme | PRODRUGS OF HIV INVERTER TRANSCRIPTASE INHIBITOR |
-
2013
- 2013-09-20 EP EP13840379.5A patent/EP2900240B1/en active Active
- 2013-09-20 BR BR112015005997A patent/BR112015005997A8/pt not_active Application Discontinuation
- 2013-09-20 CA CA2882947A patent/CA2882947A1/en not_active Abandoned
- 2013-09-20 CN CN201811295039.5A patent/CN109384765A/zh active Pending
- 2013-09-20 MX MX2015003767A patent/MX362517B/es active IP Right Grant
- 2013-09-20 JP JP2015534567A patent/JP6387349B2/ja active Active
- 2013-09-20 ES ES13840379T patent/ES2773105T3/es active Active
- 2013-09-20 US US14/430,657 patent/US9150539B2/en active Active
- 2013-09-20 CN CN201380050220.9A patent/CN104684557A/zh active Pending
- 2013-09-20 WO PCT/US2013/060787 patent/WO2014052171A1/en not_active Ceased
-
2017
- 2017-09-06 JP JP2017170788A patent/JP2018024683A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP6387349B2 (ja) | 2018-09-05 |
| JP2015531372A (ja) | 2015-11-02 |
| WO2014052171A1 (en) | 2014-04-03 |
| BR112015005997A8 (pt) | 2023-04-11 |
| BR112015005997A2 (pt) | 2017-07-04 |
| CA2882947A1 (en) | 2014-04-03 |
| CN109384765A (zh) | 2019-02-26 |
| EP2900240B1 (en) | 2020-01-08 |
| ES2773105T3 (es) | 2020-07-09 |
| CN104684557A (zh) | 2015-06-03 |
| EP2900240A1 (en) | 2015-08-05 |
| EP2900240A4 (en) | 2016-07-13 |
| US20150232447A1 (en) | 2015-08-20 |
| JP2018024683A (ja) | 2018-02-15 |
| US9150539B2 (en) | 2015-10-06 |
| MX2015003767A (es) | 2015-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA519402405B1 (ar) | مركبات مثبط فيروس نقص المناعة البشري | |
| MA38182A1 (fr) | Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih) | |
| CY1124043T1 (el) | Εξουδετερωτικα αντισωματα του ανθρωπινου ιου της ανοσοανεπαρκειας και μεθοδοι χρησης αυτων | |
| NZ598766A (en) | Macrocyclic integrase inhibitors | |
| TR201905009T4 (tr) | Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları. | |
| MX376969B (es) | Anticuerpos anti-vih ampliamente neutralizantes. | |
| EA201101620A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| CY1118774T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει εναν μη νουκλεοσιδικο αναστολεα αναστροφης μεταγραφασης | |
| MX2009013349A (es) | Compuestos quimicos. | |
| MX2013005478A (es) | Compuestos heterociclicos condensados antivirales. | |
| EP3757105A3 (en) | Polycyclic pyridone derivative having integrase inhibitory activity | |
| EA201000777A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| MX362517B (es) | Forma cristalina de un inhibidor de transcriptasa inversa. | |
| EA202191711A1 (ru) | Производные пиримидона в качестве селективных цитотоксических агентов против вич-инфицированных клеток | |
| WO2013132208A8 (en) | Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine | |
| SG178909A1 (en) | Generation of a broad t-cell response in humans against hiv | |
| EA201101397A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| BR112014003989A2 (pt) | composto, composições e métodos para inibir a replicação do hiv-1 em paciente, para tratar pacientes infectados com hiv/aids e para profilaxia de pré-exposição para tratar paciente e para prevenir a transmissão de pessoa infectada para pessoa não infectada | |
| JP2013508349A5 (OSRAM) | ||
| EP2521733A4 (en) | HIGHLY CONSERVED HUMAN IMMUNODEFICIENCY VIRUS (HIV-1) AND SMALL-VARIANT SEQUENCES THEREOF AS AIMS FOR VACCINATORY AND DIAGNOSIS USES | |
| CL2012002743A1 (es) | Combinación que comprende maraviroc, un inhibidor de proteasa de vih-1 y un potenciador famacocinetico, uso en la preparacion de un medicamento util en el tratmiento de infeccion por vih. | |
| WO2007098247A3 (en) | Substituted taraxastanes useful for treating viral infections | |
| Polo-Megías et al. | Potent HIV-1 miniprotein inhibitors targeting highly conserved gp41 epitopes | |
| BR112021023204A2 (pt) | Composto, composição farmacêutica, métodos para tratar infecção por hiv, para induzir dimerização de gag-pol em células infectadas por hiv, para matar seletivamente células expressoras de gag-pol infectadas por hiv e para aumentar a supressão de viremia do hiv, e, uso de um composto | |
| WO2015084763A3 (en) | Process for making reverse transcriptase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |